6-methyl-1-oxa-6-azaspiro<2.5>octane | 67685-99-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 6-methyl-1-oxa-6-azaspiro<2.5>octane
• 英文别名: N-Methyl-2-oxo-6-azaspiro<2.5>octan；6-methyl-1-oxa-6-aza-spiro[2.5]octane；6-methyl-1-Oxa-6-azaspiro[2.5]octane
• CAS: 67685-99-8
• 化学式: C₇H₁₃NO
• mdl: MFCD11046438
• 分子量: 127.186
• InChiKey: MAHAWHHIYVFTTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-甲基-4-哌啶酮 、 三甲基氯化亚砜 在 sodium hydride 作用下， 生成 6-methyl-1-oxa-6-azaspiro<2.5>octane
  参考文献：
  名称：

  Satyamurthy, Nagichettiar; Berlin, K. Darrell; Hossain, M. Bilayet, Phosphorus and Sulfur and the Related Elements, 1984, vol. 19, p. 113 - 130

  摘要：

  DOI：

文献信息

• [EN] INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO)<br/>[FR] INHIBITEUR DE L'INDOLÉAMINE-2,3-DIOXYGÉNASE (IDO)
  申请人：INVENTISBIO INC

  公开号：WO2017139414A1

  公开（公告）日：2017-08-17

  The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

  本公开提供了式（I）的化合物。本文描述的化合物可能在治疗与IDO相关的疾病方面有用，例如癌症或传染病（例如病毒或细菌感染性疾病）。本公开还提供了包括或使用本文描述的化合物的药物组合物、试剂盒、方法和用途。
• SERINE/THREONINE KINASE INHIBITORS
  申请人：GENENTECH, INC.

  公开号：US20150031674A1

  公开（公告）日：2015-01-29

  Compounds having the formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R a , R b , R c , R d , R e , n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

  具有公式I的化合物，其中R1、R2、R3、R4、R5、Ra、Rb、Rc、Rd、Re、n、r、s和t的定义如本文所述，并且这些化合物是PAK1的抑制剂。还公开了用于治疗癌症和过度增殖性疾病的组合物和方法。
• [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011084402A1

  公开（公告）日：2011-07-14

  The present invention relates to pyridazin-4(1H)-one derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

  本发明涉及吡啶并嗪-4(1H)-酮衍生物，用于治疗细胞增殖性疾病，治疗与MET活性相关的疾病，并抑制受体酪氨酸激酶MET。该发明还涉及包含这些化合物的组合物，以及利用它们治疗哺乳动物癌症的方法。
• Oxazinoquinolones useful for the treatment of viral infections
  申请人：——

  公开号：US20020103170A1

  公开（公告）日：2002-08-01

  The present invention provides a compound of formula I 1 which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.

  本发明提供了一种化合物I1的公式，该化合物可用作抗病毒剂，特别是用作抗疱疹病毒家族的药剂。
• [EN] HYDROXYLATED DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN<br/>[FR] DÉRIVÉS HYDROXYLÉS DE COMPOSÉS DE 1-OXA-4,9-DIAZASPIRO-UNDÉCANE AYANT UNE ACTIVITÉ MULTIMODALE CONTRE LA DOULEUR
  申请人：ESTEVE PHARMACEUTICALS SA

  公开号：WO2020157026A1

  公开（公告）日：2020-08-06

  The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the µ-opioid receptor and more particularly to hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

  本发明涉及具有对σ受体和µ-阿片受体具有双重药理活性的化合物，更具体地涉及具有这种药理活性的1-氧-4,9-二氮杂螺十一烷化合物的羟基衍生物，以及制备这些化合物的方法，包括它们的药物组合物，以及它们在治疗中的应用，特别是用于疼痛治疗。